MPM Oncology Impact Management »

Protagonist Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Protagonist Therapeutics (PTGX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Protagonist Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protagonist Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protagonist Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $17M 200k 87.34

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Protagonist Therapeutics

BlackRock
Farallon Capital Management
Vanguard Group
Rtw Investments
State Street Corporation
UBS Group
BVF
Johnson & Johnson
Wellington Management Company
Invesco
Geode Capital Management
Woodline Partners
Driehaus Capital Management
Henderson Group
ADAR1 Capital Management

View all funds holding Protagonist Therapeutics